The company plans to launch a Phase I trial of its lead autologous cell therapy for renal cell carcinoma in 2026.

The firm expects to begin the Phase I trial in HER2-positive breast and gastric cancers in the first half of 2026.

The nonprofit subsidiary Orphan Therapies will be the exclusive commercializaiton partner for the Wiskott-Aldrich syndrome gene therapy in the US.

Experts at SABCS said better prospective trials of ctDNA and more sensitive assays could bring ctDNA testing closer to the ...

The firm will share updated data and new analyses from its Phase III trial with the agency, which issued a complete response ...

The FDA's approval is based on results from the Phase III DESTINY-Breast09 trial, in which the combo showed a median 40.7-month progression-free survival.

Lunit will use two of its AI-based SCOPE platform to analyze immunohistochemistry slides and the tumor microenvironment.

Anavex had proposed restricting the drug's indication to patients with early Alzheimer's without mutations in the SIGMAR1 gene.

The SERD improved survival endpoints compared to standard adjuvant endocrine therapy in a Phase III trial that may support ...

The trial results support Tukysa-Herceptin-Perjeta as yet another option for breast cancer patients in the frontline ...

Challenging federal funding cuts, minimal residual disease, and a busy field of CAR T-cell candidates characterized this year ...

NEW YORK – TransCode Therapeutics' microRNA-10b inhibitor TTX-MC138 will be included in a Phase II branch of the PRE-I-SPY trial, the company announced Thursday.